Clinical trials: Chronic Obstructive
Chronic Obstructive Pulmonary Disorder
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg)…
- Trial name
- telos (NCT02766608)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg
- Where
- 259 sites in United States, Canada and 6 more
- Volunteers
- 2,389 people
- Sponsor
- Pearl Therapeutics, Inc.
Leukemia
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.
- Trial name
- NCT01357655
- Testing
- Dasatinib, BMS-833923
- Where
- 24 sites in United States, Argentina and 6 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Asthma, COPD
The Effects of Broccoli Sprout Extract on Obstructive Lung Disease
The purpose of this study is to examine whether broccoli sprout extract can effect lung function measurements in individuals with asthma and COPD.
- Trial name
- NCT00994604
- Testing
- broccoli sprout extract
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Chronic, Intractable Pain of the Trunk and/or Lower Limbs
Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial
Prospective, multi-center, randomized, single blind study
- Trial name
- DELIVERY (NCT03277378)
- Testing
- lead placement followed by BurstDR stimulation
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 270 people
- Sponsor
- Abbott Medical Devices
Pulmonary Disease, Chronic Obstructive
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
The purpose of this study is to evaluate the efficacy and safety of the FSC HFA MDI in subjects with COPD. The dose of FSC HFA MDI to be evaluated corresponds to the dose of FSC DISKUS (250/50mcg twice-daily) that is indicated…
- Trial name
- NCT00633217
- Testing
- Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
- Where
- 16 sites in United States
- Volunteers
- 247 people
- Sponsor
- GlaxoSmithKline
COPD
Vector Engineering Clinical
This study aimed to validate a novel automatic non-invasive ventilation (NIV) mode that continuously adjusts expiratory positive airway pressure (EPAP) to the lowest value that abolishes tidal expiratory flow limitation (EFL).
- Trial name
- NCT04725500
- Testing
- Auto-Titrating EPAP
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients…
- Trial name
- RESONATE™ (NCT01578707)
- Testing
- ofatumumab, ibrutinib
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 391 people
- Sponsor
- Pharmacyclics LLC.
COPD
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
This study will investigate whether switching symptomatic COPD patients from a fixed-dose combination of salmeterol/fluticasone 50/500 µg b.i.d. to a fixed dose combination of QVA149 110/50 µg o.d.
- Trial name
- FLASH (NCT02516592)
- Testing
- QVA149 110/50 micrograms, Salmeterol/fluticasone 50/500 microgrammes
- Where
- 64 sites in Australia, Egypt and 9 more
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection.
- Trial name
- NCT02105948
- Testing
- Mepolizumab
- Where
- 116 sites in United States, Australia and 14 more
- Volunteers
- 837 people
- Sponsor
- GlaxoSmithKline
COPD
A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the study is to propose that roflumilast is associated with meaningful reductions in biomarkers of pulmonary inflammation and sputum neutrophilia, including confirmation of previously described results, and…
- Trial name
- NCT01572948
- Testing
- roflumilast
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Alabama at Birmingham
Spinal Cord Injury, Sleep Apnea, Obstructive
Sleep-Disordered Breathing in Chronic SCI
The purpose of this study is to examine impact of Sleep Disordered Breathing (SDB) treatment in persons with chronic Spinal Cord Injury (SCI).
- Trial name
- NCT02176928
- Testing
- AutoPAP
- Where
- 4 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Miami
Pulmonary Disease, Chronic Obstructive
Drug Use Survey of RESPIMAT in Patients With COPD
To investigate safety and effectiveness information on the use of Tiotropium Respimat for long time of period in daily practical clinical circumstances, and to obtain proper drug use information.
- Trial name
- NCT01145053
- Volunteers
- 361 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice
The purpose of this study is to monitor the change in the health status of severe COPD patients after the initiation of Tiotropium therapy.
- Trial name
- NCT00624377
- Testing
- Tiotropium
- Where
- 17 sites in Taiwan
- Volunteers
- 2,031 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals.
- Trial name
- LEUKO (NCT00493974)
- Testing
- Zileuton
- Where
- 18 sites in United States
- Volunteers
- 119 people
- Sponsor
- University of Minnesota
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Graft Versus Host Disease, Ophthalmologic Complications
Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease
This phase II clinical trial studies how well bandage lenses work in treating patients with ocular graft versus host disease. Bandage lenses may be helpful in relieving eye symptoms and damage caused by eye graft versus host…
- Trial name
- NCT01616056
- Testing
- graft versus host disease prophylaxis/therapy, questionnaire administration, optical coherence tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Evaluate the…
- Trial name
- AERIFY-1 (NCT04701983)
- Testing
- Itepekimab SAR440340
- Where
- 232 sites in United States, Argentina and 19 more
- Volunteers
- 1,127 people
- Sponsor
- Sanofi
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+) malignant disease.
- Trial name
- NCT01680991
- Testing
- Obinutuzumab
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
COPD
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for…
- Trial name
- GOLDEN-3 (NCT02347761)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer
- Where
- 44 sites in United States
- Volunteers
- 653 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT04535986
- Testing
- Ensifentrine
- Where
- 122 sites in United States, Bulgaria and 10 more
- Volunteers
- 763 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA